Zenicure Labs

Dapagod‑10 (Dapagliflozin 10mg Tablet) is a SGLT2 inhibitor indicated for the management of type 2 diabetes mellitus and cardiovascular/renal protection. It is part of the modern class of antidiabetic drugs that not only lower blood sugar but also provide additional benefits in heart and kidney health.

• Type 2 Diabetes Mellitus

  • Improves glycemic control by promoting urinary glucose excretion.

• Heart Failure (HFrEF & HFpEF)

  • Reduces hospitalization and improves outcomes in patients with heart failure.

• Chronic Kidney Disease (CKD)

  • Slows progression of renal impairment and reduces risk of end‑stage kidney disease.

• Weight & Blood Pressure Benefits

  • Promotes modest weight loss and lowers systolic blood pressure.

Diasky‑M (Gliclazide 80mg + Metformin 500mg Tablet) is a dual oral antidiabetic therapy designed for effective glycemic control in type 2 diabetes mellitus. It combines a sulfonylurea with biguanide for complementary action.

• Type 2 Diabetes Mellitus

  • Improves glycemic control when diet and exercise alone are insufficient.

• Combination Therapy

  • Effective in patients not controlled with monotherapy.

• Prevention of Diabetes Complications

  • Reduces risk of microvascular (retinopathy, nephropathy) and macrovascular (cardiovascular) complications.

Empagod‑25 (Empagliflozin 25mg Tablet) is a SGLT2 inhibitor widely used in modern diabetes and cardiovascular care.

• Type 2 Diabetes Mellitus

  • Improves glycemic control by increasing urinary glucose excretion.

• Cardiovascular Protection

  • Reduces risk of cardiovascular death in patients with type 2 diabetes and established heart disease.

  • Lowers hospitalization rates for heart failure (both HFrEF & HFpEF).

• Chronic Kidney Disease (CKD)

  • Slows progression of renal impairment and reduces risk of end‑stage kidney disease.

• Additional Benefits

  • Promotes modest weight loss.

  • Helps lower systolic blood pressure.

Empagod‑M (Empagliflozin 12.5mg + Metformin 500mg Tablet) is a dual oral antidiabetic therapy combining an SGLT2 inhibitor with a biguanide for comprehensive glycemic control and cardio‑renal protection.

• Type 2 Diabetes Mellitus

  • Improves blood sugar control when diet, exercise, or monotherapy are insufficient.

• Cardiovascular Protection

  • Empagliflozin reduces risk of cardiovascular death and hospitalization for heart failure.

• Renal Benefits

  • Slows progression of chronic kidney disease and reduces risk of end‑stage renal disease.

• Metabolic Benefits

  • Promotes modest weight loss and lowers systolic blood pressure.

Empagod‑L (Empagliflozin 25mg + Linagliptin 5mg Tablet) is a dual oral antidiabetic therapy combining an SGLT2 inhibitor with a DPP‑4 inhibitor for comprehensive glycemic control and cardio‑renal protection.

• Type 2 Diabetes Mellitus

  • Improves glycemic control when diet, exercise, or monotherapy are insufficient.

  • Suitable for patients needing both insulin sensitivity improvement and incretin‑based support.

• Cardiovascular Protection (Empagliflozin component)

  • Reduces risk of cardiovascular death and hospitalization for heart failure.

• Renal Benefits (Empagliflozin component)

  • Slows progression of chronic kidney disease and reduces risk of end‑stage renal disease.

• Weight & Metabolic Benefits

  • Empagliflozin promotes modest weight loss and lowers blood pressure.

  • Linagliptin is weight‑neutral and safe in renal impairment.

Sitamove‑DM (Dapagliflozin 10mg + Sitagliptin 100mg + Metformin 500mg Tablet) is a triple oral antidiabetic therapy designed for comprehensive glycemic control and cardio‑renal protection. It combines three modern mechanisms: SGLT2 inhibition, DPP‑4 inhibition, and insulin sensitization.

• Type 2 Diabetes Mellitus

  • Provides strong glycemic control when monotherapy or dual therapy is insufficient.

• Cardiovascular Protection (Dapagliflozin)

  • Reduces risk of cardiovascular death and hospitalization for heart failure.

• Renal Benefits (Dapagliflozin)

  • Slows progression of chronic kidney disease and reduces risk of end‑stage renal disease.

• Post‑meal Glucose Control (Sitagliptin)

  • Enhances incretin hormones → increases insulin release, decreases glucagon → lowers post‑prandial glucose.

• Insulin Sensitivity & Weight Benefits (Metformin)

  • Reduces hepatic glucose production, improves insulin sensitivity, modest weight loss.

Sitamove‑M (Sitagliptin 50mg + Metformin 500mg Tablet) is a dual oral antidiabetic therapy combining a DPP‑4 inhibitor with a biguanide for balanced glycemic control.

• Type 2 Diabetes Mellitus

  • Improves blood sugar control when diet, exercise, or monotherapy are insufficient.

• Post‑meal Glucose Control (Sitagliptin)

  • Enhances incretin hormones → increases insulin release, decreases glucagon → lowers post‑prandial glucose.

• Fasting Glucose Control (Metformin)

  • Reduces hepatic glucose production, improves insulin sensitivity, lowers fasting glucose.

• Combination Advantage

  • Targets insulin secretion + insulin sensitivity, offering comprehensive glycemic control.

Tenrise‑20 (Teneligliptin 20mg Tablet) is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus. It enhances incretin activity, helping regulate both fasting and post‑meal glucose levels.

• Type 2 Diabetes Mellitus

  • Improves glycemic control when diet, exercise, or monotherapy are insufficient.

• Post‑meal Glucose Control

  • Increases insulin secretion and decreases glucagon release via incretin pathway.

• Weight Neutral

  • Unlike some antidiabetic drugs, Teneligliptin does not cause weight gain.

• Renal Safety

  • Can be used in patients with mild to moderate renal impairment.

Vildair‑D (Dapagliflozin 10mg + Vildagliptin SR 100mg Bilayered Tablet) is a dual oral antidiabetic therapy combining an SGLT2 inhibitor with a DPP‑4 inhibitor in a bilayered sustained‑release format for comprehensive glycemic control and cardio‑renal protection.

• Type 2 Diabetes Mellitus

  • Provides strong glycemic control when monotherapy or dual therapy is insufficient.

• Cardiovascular Protection (Dapagliflozin)

  • Reduces risk of cardiovascular death and hospitalization for heart failure.

• Renal Benefits (Dapagliflozin)

  • Slows progression of chronic kidney disease and reduces risk of end‑stage renal disease.

• Post‑meal Glucose Control (Vildagliptin SR)

  • Enhances incretin hormones → increases insulin release, decreases glucagon → lowers post‑prandial glucose.

• Metabolic Benefits

  • Dapagliflozin promotes modest weight loss and lowers blood pressure.

  • Vildagliptin is weight‑neutral and safe in renal impairment.

Vildair‑M (Vildagliptin 50mg + Metformin 1000mg Tablet) is a dual oral antidiabetic therapy combining a DPP‑4 inhibitor with a biguanide for comprehensive glycemic control.

• Type 2 Diabetes Mellitus

  • Improves glycemic control when diet, exercise, or monotherapy are insufficient.

• Post‑meal Glucose Control (Vildagliptin)

  • Enhances incretin hormones → increases insulin release, decreases glucagon → lowers post‑prandial glucose.

• Fasting Glucose Control (Metformin)

  • Reduces hepatic glucose production, improves insulin sensitivity, lowers fasting glucose.

• Combination Advantage

  • Targets incretin pathway + insulin sensitivity, offering balanced control of both fasting and post‑meal glucose.

Zesky‑500 (Metformin Hydrochloride Sustained Release 500mg Tablet) is a biguanide class oral antidiabetic used as first‑line therapy in type 2 diabetes mellitus. The sustained‑release (SR) formulation improves tolerability and patient compliance.

• Type 2 Diabetes Mellitus

  • First‑line therapy to improve glycemic control.

  • Reduces fasting blood glucose and HbA1c.

• Insulin Sensitization

  • Improves peripheral glucose uptake and utilization.

• Hepatic Glucose Control

  • Decreases hepatic glucose production.

• Weight & Metabolic Benefits

  • Weight‑neutral or modest weight reduction.

  • May improve lipid profile.

Zesky‑M1 (Glimepiride 1mg + Metformin Hydrochloride 500mg SR Bilayered Tablet) is a dual oral antidiabetic therapy combining a sulfonylurea with a biguanide in a sustained‑release bilayered format for effective and durable glycemic control.

• Type 2 Diabetes Mellitus

  • Improves glycemic control when diet, exercise, or monotherapy are insufficient.

• Fasting Glucose Control (Metformin SR)

  • Reduces hepatic glucose production, improves insulin sensitivity, lowers fasting glucose.

• Insulin Secretion Support (Glimepiride)

  • Stimulates pancreatic beta cells to release insulin → lowers post‑prandial glucose.

• Combination Advantage

  • Targets insulin secretion + insulin sensitivity, offering comprehensive control of both fasting and post‑meal glucose.

• Bilayered Sustained Release

  • Ensures gradual release, reduced GI side effects, and better patient compliance.

Zesky‑M1 (Glimepiride 1mg + Metformin Hydrochloride 1000mg SR Bilayered Tablet) is a dual oral antidiabetic therapy combining a sulfonylurea with a biguanide in a sustained‑release bilayered format for effective and durable glycemic control.

• Type 2 Diabetes Mellitus

  • Improves glycemic control when diet, exercise, or monotherapy are insufficient.

• Fasting Glucose Control (Metformin SR)

  • Reduces hepatic glucose production, improves insulin sensitivity, lowers fasting glucose.

• Insulin Secretion Support (Glimepiride)

  • Stimulates pancreatic beta cells to release insulin → lowers post‑prandial glucose.

• Combination Advantage

  • Targets insulin secretion + insulin sensitivity, offering comprehensive control of both fasting and post‑meal glucose.

• Bilayered Sustained Release

  • Ensures gradual release, reduced GI side effects, and better patient compliance.

Zesky‑M2 (Glimepiride 2mg + Metformin Hydrochloride 1000mg SR Bilayered Tablet) is a dual oral antidiabetic therapy combining a sulfonylurea with a biguanide in a sustained‑release bilayered format for effective and durable glycemic control.

• Type 2 Diabetes Mellitus

  • Provides glycemic control when diet, exercise, or monotherapy are insufficient.

• Fasting Glucose Control (Metformin SR)

  • Reduces hepatic glucose production, improves insulin sensitivity, lowers fasting glucose.

• Insulin Secretion Support (Glimepiride)

  • Stimulates pancreatic beta cells to release insulin → lowers post‑prandial glucose.

• Combination Advantage

  • Targets insulin secretion + insulin sensitivity, offering comprehensive control of both fasting and post‑meal glucose.

• Bilayered Sustained Release

  • Ensures gradual release, reduced GI side effects, and better patient compliance.

Zesky‑Mv2 (Glimepiride 2mg + Metformin Hydrochloride 500mg + Voglibose 0.2mg Bilayered Tablet) is a triple oral antidiabetic therapy combining a sulfonylurea, a biguanide, and an alpha‑glucosidase inhibitor in a bilayered sustained‑release format for comprehensive glycemic control.

• Type 2 Diabetes Mellitus

  • Provides strong glycemic control when monotherapy or dual therapy are insufficient.

• Fasting Glucose Control (Metformin SR)

  • Reduces hepatic glucose production, improves insulin sensitivity, lowers fasting glucose.

• Insulin Secretion Support (Glimepiride)

  • Stimulates pancreatic beta cells to release insulin → lowers post‑prandial glucose.

• Post‑meal Glucose Control (Voglibose)

  • Delays intestinal carbohydrate absorption → reduces post‑prandial glucose spikes.

• Combination Advantage

  • Targets insulin secretion + insulin sensitivity + carbohydrate absorption, offering comprehensive control of fasting and post‑meal glucose.

• Bilayered Sustained Release

  • Ensures gradual release, reduced GI side effects, and better patient compliance.

Zesky‑M2 (Glimepiride 2mg + Metformin Hydrochloride 500mg SR Bilayered Tablet) is a dual oral antidiabetic therapy combining a sulfonylurea with a biguanide in a sustained‑release bilayered format for effective and durable glycemic control.

• Type 2 Diabetes Mellitus

  • Improves glycemic control when diet, exercise, or monotherapy are insufficient.

• Fasting Glucose Control (Metformin SR)

  • Reduces hepatic glucose production, improves insulin sensitivity, lowers fasting glucose.

• Insulin Secretion Support (Glimepiride)

  • Stimulates pancreatic beta cells to release insulin → lowers post‑prandial glucose.

• Combination Advantage

  • Targets insulin secretion + insulin sensitivity, offering comprehensive control of both fasting and post‑meal glucose.

• Bilayered Sustained Release

  • Ensures gradual release, reduced GI side effects, and better patient compliance.

Protein Powder with Vitamins & Minerals (Vanilla Flavour, Sugar‑Free) is a nutritional supplement designed to support energy, muscle recovery, and overall wellness, especially for individuals managing diabetes, weight, or lifestyle‑related conditions.

• High‑quality protein source → supports muscle repair, strength, and satiety.

• Fortified with vitamins & minerals → boosts immunity, energy metabolism, and bone health.

• Sugar‑free formulation → safe for diabetics and calorie‑conscious individuals.

• Vanilla flavour → smooth taste, easy to mix with milk or water.

• Balanced nutrition

Tenrise‑M (Teneligliptin 20mg + Metformin 1000mg SR Bilayered Tablet) is a dual oral antidiabetic therapy combining a DPP‑4 inhibitor with a biguanide in a sustained‑release bilayered format for durable glycemic control.

• Type 2 Diabetes Mellitus

  • Improves blood sugar control when diet, exercise, or monotherapy are insufficient.

• Post‑meal Glucose Control (Teneligliptin)

  • Enhances incretin hormones → increases insulin release, decreases glucagon → lowers post‑prandial glucose.

• Fasting Glucose Control (Metformin SR)

  • Reduces hepatic glucose production, improves insulin sensitivity, lowers fasting glucose.

• Combination Advantage

  • Targets incretin pathway + insulin sensitivity, offering comprehensive control of both fasting and post‑meal glucose.

• Bilayered Sustained Release

  • Ensures stable release, reduced GI side effects, and improved patient compliance.

Tenrise‑M (Teneligliptin 20mg + Metformin 500mg HCl ER Bilayered Tablet) is a dual oral antidiabetic therapy combining a DPP‑4 inhibitor with a biguanide in an extended‑release bilayered format for sustained and balanced glycemic control.

• Type 2 Diabetes Mellitus

  • Improves glycemic control when diet, exercise, or monotherapy are insufficient.

• Post‑meal Glucose Control (Teneligliptin)

  • Enhances incretin hormones → increases insulin release, decreases glucagon → lowers post‑prandial glucose.

• Fasting Glucose Control (Metformin ER)

  • Reduces hepatic glucose production, improves insulin sensitivity, lowers fasting glucose.

• Combination Advantage

  • Targets incretin pathway + insulin sensitivity, offering comprehensive control of both fasting and post‑meal glucose.

• Bilayered Extended Release

  • Ensures stable release, better tolerability, and improved patient compliance.

Vildair‑M (Vildagliptin 50mg + Metformin 500mg Tablet) is a dual oral antidiabetic therapy combining a DPP‑4 inhibitor with a biguanide for balanced and durable glycemic control.

• Type 2 Diabetes Mellitus

  • Improves glycemic control when diet, exercise, or monotherapy are insufficient.

• Post‑meal Glucose Control (Vildagliptin)

  • Enhances incretin hormones → increases insulin release, decreases glucagon → lowers post‑prandial glucose.

• Fasting Glucose Control (Metformin)

  • Reduces hepatic glucose production, improves insulin sensitivity, lowers fasting glucose.

• Combination Advantage

  • Targets incretin pathway + insulin sensitivity, offering comprehensive control of both fasting and post‑meal glucose.